Knopp Biosciences Announces Publication of Eosinophil-lowering Effects of Dexpramipexole in Multiple Clinical Trials

Knopp Biosciences LLC announced the publication of results from multiple clinical trials demonstrating the eosinophil-lowering effects of dexpramipexole, a small molecule treatment in development for eosinophil-associated diseases.

“The totality of the evidence to date, across multiple clinical studies in multiple indications, demonstrates that dexpramipexole is a targeted eosinophil-lowering agent with eosinophil-lowering effects equal to our great than monoclonal antibodies against interleukin-5 or its receptor,” said Michael Bozik, M.D., president and CEO of Knopp Biosciences. Read more.


Comments are closed.